Research & Development May 8, 2026 Construction begins on Novartis’ RLT centre in Texas, US By Salong Debbarma The location will serve as Novartis’ first RLT manufacturing site in Texas and is the company’s fifth such site in the country, increasing supply chain reach for the
Research & Development May 8, 2026 Angelini Pharma to acquire Catalyst Pharmaceuticals for equity value of $4.1bn By Salong Debbarma The acquisition has been approved unanimously by both companies’ boards of directors, with the transaction expected to close in the third quarter of 2026. Angelini Pharma will purchase
Research & Development May 7, 2026 Daiichi Sankyo and Waiv partner for ADC biomarkers By Salong Debbarma Waiv will use its computational pathology platform to work with early phase data, which will involve analysis of tumour microenvironments using haematoxylin and eosin (H&E), as well as
Research & Development May 7, 2026 Halozyme and Oruka sign agreement for Hypercon technology By Salong Debbarma Oruka has licensed the Halozyme technology for use with its lead programme, ORKA-001, which is in development to treat psoriasis and related inflammatory conditions, and up to one
Research & Development May 6, 2026 Citius raises $36.5m for Lymphir commercialisation By Salong Debbarma The therapy is approved by the US Food and Drug Administration (FDA) for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) following at least one prior systemic treatment. The
Research & Development May 6, 2026 MSD concludes Terns acquisition to expand CML pipeline By Salong Debbarma Following a successful tender offer and subsequent merger, the companies announced the completion of the transaction, making Terns a wholly owned subsidiary of MSD. The US Food and
Approvals May 5, 2026 Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara By Salong Debbarma Langlara is cleared for use in adults and children with type 1 diabetes mellitus (T1DM), as well as adults with type 2 diabetes mellitus (T2DM). The FDA’s decision
Research & Development May 5, 2026 Latus Bio secures $97m in funding to boost gene therapy access By Salong Debbarma The financing includes a $43m extension led by 8VC, with participation from existing investors BioAdvance, Benjamin Franklin Technology Partners, DCVC Bio, Gaingels, Hatch BioFund and Modi Ventures. New
Approvals May 4, 2026 Arrowhead’s Redemplo secures Australian TGA approval for FCS therapy By Salong Debbarma The therapy is approved as an add-on to diet, specifically for adults with FCS whose triglyceride levels remain high despite standard triglyceride-lowering treatments. The approval marks an expansion
Production & Sales May 4, 2026 Novo Nordisk to launch Ozempic for type 2 diabetes in US By Salong Debbarma The Ozempic oral pill, approved by the Food and Drug Administration (FDA), offers an option for adults with type 2 diabetes to manage blood sugar and cardiovascular risk